AzTrials
AzTrials

Intermittent HypoxiaNCT05463042

Intermittent Hypoxia and Balance Control

A study testing Intermittent Hypoxia in people with Intermittent Hypoxia and Normoxia, run by University of Texas at Austin at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aims to determine the effect of acute mild intermittent hypoxia on ankle plantarflexor muscle output during balance regulation and walking in younger and older adults. Read more about this study

Who is it for?
Ages 18 to 80 yearsHealthy volunteers can take part
Conditions the study is for
Intermittent Hypoxia, Normoxia
What is being tested?
Intermittent Hypoxia
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
3 participants
Where
1 siteUnited States
Study dates
1 Sep 2022to 21 Aug 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Able to stand and walk for more than 5 minutes without assistance.

Who cannot join

  • Have high blood pressure (above 130/90 mmHg)
  • Are smokers
  • Are pregnant
  • Have body mass index more than 35 kg/m2
  • Have a history of falls in the past 6 months
  • Have a history of neuromuscular deficits that may affect gait
Show all 9Show fewer
  • Have a history of cardiovascular disease
  • Have a history of diabetes or lung disease
  • Are taking medication affecting the cardiovascular system

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Texas at Austin

    Austin, Texas, 78712

Other trials in United States

About this study

Official title: Effect of Intermittent Hypoxia on Balance Control During Standing and Walking in Healthy Adults

This study aims to determine the effect of acute mild intermittent hypoxia on ankle plantarflexor muscle output during balance regulation and walking in younger and older adults. Fifteen younger adults and 15 older adults will be recruited to participate in the cross-over design study that requires 2 visits (at least 1-week apart). Participants will be pseudo-randomly assigned to receive either intermittent hypoxia or sham during the first visit, and then switch over to receive sham or intermittent hypoxia during the 2nd visit. Muscle activation patterns and kinetic and kinematics during standing and walking will be recorded before and after the intermittent hypoxia/sham. It is hypothesized that compared to the sham condition, both younger and older participants will show greater increases in ankle plantarflexor muscle activation during gait and balance assessments following intermittent hypoxia.

Read the detailed description

Procedure:

This is a cross-over design study that requires 2 visits (at least 1-week apart). Fifteen younger adults and 15 older adults will be recruited. Participants will be pseudo-randomly assigned to receive either intermittent hypoxia or sham during the first visit, and then switch over to receive sham or intermittent hypoxia during the 2nd visit.

During each visit, participants will first perform Gait and Balance Assessments (PRE), followed by the Intermittent Hypoxia (or sham) protocol, and then perform Gait and Balance Assessments (POST) again. The total time is approximately 2.5 hours for each visit.

Balance and Gait Assessments The consent process and Balance and Gait Assessments will take place in BEL 530.

During Balance and Gait Assessments, participants will be asked to wear tight-fitting shorts and shirt for accurate marker positioning. Approximately 39 reflective markers will be attached to target locations on the individuals' body (the head, arms, wrists, hands, trunk, pelvis, legs and feet) according to the Vicon Full-Body Plug-In Gait Model.

A study team member will attach surface electrodes over the tibialis anterior and soleus muscles to record the muscle activation patterns with a wireless Electromyography (EMG) system (Delsys Inc., Natick, MA). Next, a study team member will assist the participant to wear a safety harness that will be attached to an overhead support beam.

For Balance Assessment, participants will stand on the treadmill with their feet shoulder-width apart. A 30-second quiet standing trial will be recorded. Next, participants will be instructed to maintain upright posture when the treadmill shifts forward or backward at unknown times (perturbed standing). The treadmill will shift approximately 3 cm. Based on our previous experiment, this distance is sufficient to trigger a response without inducing a fall. Three forward and 3 backward treadmill shifts will be delivered in a randomized order. Finally, participants will be asked to close their eyes and repeat the quiet standing and perturbed standing trials. A 10-camera Vicon Nexus motion capture system (Vicon, Oxford Metrics, UK) will be used to record whole body kinematics. Ground reaction forces under each belt will be recorded. A handrail is located on either side of the treadmill.

For Gait Assessments, participants will walk on the treadmill at their comfortable and fast walking speeds. The comfortable speed will be determined by gradually increasing the treadmill speed until the participant confirms that it reaches their comfortable regular walking speed. The fast speed will be determined by gradually increasing the treadmill speed until the participant confirms that it reaches the maximum speed that they can walk safely. A 30-second walking trial will be recorded for each speed.

Following Balance and Gait Assessment, a testing team member will escort the participant to BEL819 Clinical Exercise Physiology Laboratory to perform Intermittent Hypoxia (or sham).

Intermittent hypoxia Intermittent hypoxia will be performed in BEL819 Clinical Exercise Physiology Laboratory. Intermittent hypoxia is routinely performed in this laboratory (IRB protocols 2017090015, 2018110129, 2019070088, and 202005018). Intermittent hypoxia consisting of a limited number (5-10/day) of short (4-10 min) bouts of mild hypoxia (oxygen levels between 10-12%) leads to cumulative and sustained beneficial physiological responses. Preliminary data collected in the Clinical Exercise Physiology Laboratory show that a fraction of oxygen of 11±1% corresponds to an arterial oxygen saturation of 80±2% in middle-aged individuals. Participants will be sitting during the entire breathing protocol. Hypoxic air will be inhaled through a mask connected to a two-way non-rebreathing valve, which will itself be connected to a 5-liter non-diffusing gas bag (Hans Rudolph, Inc, USA). The rebreathing bag will be connected to a certified medical grade gas tank containing 11% oxygen and a balance of nitrogen. The intermittent hypoxia protocol will consist of eight 4-min cycles of breathing hypoxic air interspersed with normoxic cycles breathing room air. After four min of hypoxia, participants will be switched back to breathing room air until resaturation, which takes approximately one minute. Once arterial oxygen saturation reaches baseline levels, participants will be switched back to breathing hypoxic air, beginning the next hypoxic cycle. Unlike chronic hypoxic exposure, risks associated with an acute hypoxic exposure of three 4-min cycles are minimal, and no adverse events were reported during intermittent hypoxia in our participants.

During the sham condition, compressed air (21% oxygen) from a gas tank will be delivered throughout the protocol instead of 11% oxygen. Participants will not receive information about which condition (Intermittent hypoxia or sham) they are experiencing during the trials.

Pulmonary gas exchange Breath-by-breath measures of pulmonary gas exchange such as volume of oxygen and carbon dioxide, respiratory rate, tidal volume, minute ventilation and fraction of inspired oxygen will be determined from a pneumotachometer (Ultima Cardio2, MGC Diagnostics, MN, USA) throughout the intermittent hypoxia. The pneumotachometer will be mounted between the mask and the non-rebreathing valve of the breathing circuit. The pneumotachometer, mouthpiece and non-rebreathing valve will be disinfected in a 10% bleach and water solution for 60 minutes and rinse thoroughly with tap water for 5 minutes between each use. Each participant will have a face mask that will only be used by him/her.

Hemodynamics An arterial waveform obtained by finger plethysmography from the middle finger of the left hand will be continuously recorded (NOVA, Finapres Medical Systems, Amsterdam, Netherlands) during the intermittent hypoxia. Systolic, diastolic and mean arterial pressure, heart rate, stroke volume, cardiac output and total peripheral resistance will be derived from the arterial waveform, a method which has been validated against invasive measures [9]. All data will be recorded in LabChart (Powerlab, ADInstruments Inc., CO, USA) for later analysis.

Arterial oxygen saturation Arterial oxygen saturation will continuously be monitored by pulse oximetry (NOVA, Finapres Medical Systems, Amsterdam, Netherlands) throughout the intermittent hypoxia. The pulse oximeter probe will be applied to the index finger of the left hand.

Following intermittent hypoxia (or sham), a testing team member will escort the participant back to BEL530 to perform Balance and Gait Assessment. After the assessment, a testing team member will remove the electrodes and markers from the participant.

Being tested
Intermittent Hypoxia, Normoxia (sham)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intermittent HypoxiaBehavioural

    During the intermittent hypoxia session, participants will be sitting during the entire breathing protocol. Hypoxic air will be inhaled through a mask connected to a two-way non-rebreathing valve, which will itself be connected to a 5-liter non-diffusing gas bag (Hans Rudolph, Inc, USA). The rebreathing bag will be connected to a certified medical grade gas tank containing 11% oxygen and a balance of nitrogen. The intermittent hypoxia protocol will consist of eight 4-min cycles of breathing hypoxic air interspersed with normoxic cycles breathing room air. After four min of hypoxia, participants will be switched back to breathing room air until resaturation, which takes approximately one minute. Once arterial oxygen saturation reaches baseline levels, participants will be switched back to breathing hypoxic air, beginning the next hypoxic cycle.

  • Normoxia (sham)Behavioural

    During the sham condition, compressed air (21% oxygen) from a gas tank will be delivered throughout the protocol instead of 11% oxygen. Participants will not receive information about which condition (Intermittent hypoxia or sham) they are experiencing during the trials.

Study groups in NCT05463042
Study groupRoleWhat they receive
Intermittent HypoxiaExperimentalParticipants will receive intermittent hypoxia and perform balance and gait assessments before and after the intermittent hypoxia session.
Receives: Behavioral: Intermittent Hypoxia
Normoxia (sham)Sham comparatorParticipants will receive normoxia and perform balance and gait assessments before and after the normoxia session.
Receives: Behavioral: Normoxia (sham)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Soleus muscle activation pattern

    changes in peak soleus muscle EMG magnitude following perturbation onset during standing from pre to post intermittent hypoxia will be calculated

    Measured: pre (2o minutes before) and post (20 minutes after) intermittent hypoxia or sham session

  2. Ankle plantarflexion torque

    Changes in peak ankle plantarflexion torque production during walking from pre to post intermittent hypoxia will be calculated.

    Measured: pre (20 minutes before) and post (20 minutes after) intermittent hypoxia or sham session

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jul 2022
  2. Study start1 Sep 2022
  3. Primary completion21 Aug 2023
  4. Study completion21 Aug 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
This is a cross-over design study that requires 2 visits (a least 1-week apart). Fifteen younger adults and 15 older adults will be recruited. Participants will be pseudo-randomly assigned to receive either intermittent hypoxia or sham during the first visit, and then switch over to receive sham or intermittent hypoxia during the 2nd visit.
Masking
Single blind
Who is masked
Participant
Enrolment
3 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05463042
Sponsor's protocol ID
STUDY00003081
Status last verified
Nov 2023
First submitted
8 Jul 2022
Last updated
29 Nov 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: This proposed research will include data from approximately 30 subjects regarding their walking and standing balance control mechanics. Muscle activation patterns, body movement, and force production data will be recorded. Only de-identified data will be shared for research purposes.

Publications

  • Mateika JH, El-Chami M, Shaheen D, and Ivers B. Intermittent hypoxia: a low-risk research tool with therapeutic value in humans. J Appl Physiol (1985). 2015. 118(5): 520-32. Meerson F, Pozharov V, and Minyailenko T. Superresistance against hypoxia after preliminary adaptation to repeated stress. J Appl Physiol (1985). 1994. 76(5): 1856-61. Neubauer JA. Invited review: Physiological and pathophysiological responses to intermittent hypoxia. J Appl Physiol (1985). 2001. 90(4): 1593-9. Casey DP, Shepherd JR, and Joyner MJ. Sex and vasodilator responses to hypoxia at rest and during exercise. J Appl Physiol (1985). 2014. 116(7): 927-36. Casey DP, Walker BG, Curry TB, and Joyner MJ. Ageing reduces the compensatory vasodilatation during hypoxic exercise: the role of nitric oxide. J Physiol. 2011. 589(Pt 6): 1477-88. Jarrard CP, Nagel MJ, Stray-Gundersen S, Tanaka H, and Lalande S. Hypoxic preconditioning attenuates ischemia-reperfusion injury in young healthy adults. J Appl Physiol (1985). 2021. 130(3): 846-852. Nagel MJ, Jarrard CP, and Lalande S. Effect of a Single Session of Intermittent Hypoxia on Erythropoietin and Oxygen-Carrying Capacity. Int J Environ Res Public Health. 2020. 17(19). Wojan F, Stray-Gundersen S, Nagel MJ, and Lalande S. Short exposure to intermittent hypoxia increases erythropoietin levels in healthy individuals. J Appl Physiol (1985). 2021. 130(6): 1955-1960. Wesseling KH, Jansen JR, Settels JJ, and Schreuder JJ. Computation of aortic flow from pressure in humans using a nonlinear, three-element model. J Appl Physiol (1985). 1993. 74(5): 2566-73.

Questions about this trial

What is this clinical trial studying?

A study testing Intermittent Hypoxia in people with Intermittent Hypoxia and Normoxia, run by University of Texas at Austin at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Soleus muscle activation pattern (time frame: pre (2o minutes before) and post (20 minutes after) intermittent hypoxia or sham session). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05463042, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in